3'-azido-3'-deoxy-β-(E)-5-(2-bromovinyl)-2'-deoxyuridine | 80646-52-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 3'-azido-3'-deoxy-β-(E)-5-(2-bromovinyl)-2'-deoxyuridine
• 英文别名: 3'-azido-2',3'-dideoxy-5-(E)-bromovinyluridine；3'-Azido-5-bromovinyl-2',3'-dideoxyuridine；1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-[(E)-2-bromoethenyl]pyrimidine-2,4-dione
• CAS: 80646-52-2
• 化学式: C₁₁H₁₂BrN₅O₄
• 分子量: 358.151
• InChiKey: RITJCMXQJOICCU-PIXDULNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  93.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (叔丁氧基羰基)-L-缬氨酰-L-缬氨酸 、 3'-azido-3'-deoxy-β-(E)-5-(2-bromovinyl)-2'-deoxyuridine 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以30%的产率得到3'-azido-5'-O-(N-t-butyloxycarbonyl-L-valyl-L-valinoyl)-2',3'-dideoxy-5-(E)-bromovinyluridine
  参考文献：
  名称：

  NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY

  摘要：

  该发明涉及特殊的核苷，例如，公式I所示的核苷，其中R1-R5如本文所述，并且涉及含有这些核苷的药物。此外，该发明涉及在癌症患者细胞毒治疗中抑制或减少耐药形成的方法中使用这种核苷。

  公开号：

  US20100227834A1
• 作为产物：
  描述：

  3'-azido-3'-deoxy-5'-O-triphenylmethyl-β-(E)-5-(2-bromovinyl)-2'-deoxyuridine 在 zinc dibromide 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 以90%的产率得到3'-azido-3'-deoxy-β-(E)-5-(2-bromovinyl)-2'-deoxyuridine
  参考文献：
  名称：

  3′-[4-Aryl-(1,2,3-triazol-1-yl)]-3′-deoxythymidine Analogues as Potent and Selective Inhibitors of Human Mitochondrial Thymidine Kinase

  摘要：

  In an effort to increase the potency and selectivity of earlier identified substrate-based inhibitors of mitochondrial thymidine kinase 2 (TK-2), we now describe the synthesis of new thymidine analogues containing a 4- or 5-substituted 1,2,3-triazol-1-yl substituent at the 3'-position of the 2'-deoxyribofuranosyl ring. These analogues were prepared by Cu- and Ru-catalyzed cycloadditions of 3'-azido-3'-deoxythymidine and the appropriate alkynes, which produced the 1,4- and 1,5-triazoles, respectively. Selected analogues showed nanomolar inhibitory activity for TK-2, while virtually not affecting the TK-1 counterpart. Enzyme kinetics indicated a competitive and uncompetitive inhibition profile against thymidine and the cosubstrate ATP, respectively. This behavior is rationalized by suggesting that the inhibitors occupy the substrate-binding site in a TK-2 ATP complex that maintains the enzyme's active site in a closed conformation through the stabilization of a small lid domain.

  DOI：

  10.1021/jm901532h

文献信息

• [EN] PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS<br/>[FR] COMPOSÉS DE STABILISATION DE PROTÉINE CONTENANT DES LIGANDS D'USP7
  申请人：STABLIX INC

  公开号：WO2022272133A3

  公开（公告）日：2023-02-09
• NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY
  申请人：Fahrig Rudolf

  公开号：US20100227834A1

  公开（公告）日：2010-09-09

  The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R 1 -R 5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytostatic treatment of a cancer patient.

  该发明涉及特殊的核苷，例如，公式I所示的核苷，其中R1-R5如本文所述，并且涉及含有这些核苷的药物。此外，该发明涉及在癌症患者细胞毒治疗中抑制或减少耐药形成的方法中使用这种核苷。
• 3′-[4-Aryl-(1,2,3-triazol-1-yl)]-3′-deoxythymidine Analogues as Potent and Selective Inhibitors of Human Mitochondrial Thymidine Kinase
  作者：Sara Van Poecke、Ana Negri、Federico Gago、Ineke Van Daele、Nicola Solaroli、Anna Karlsson、Jan Balzarini、Serge Van Calenbergh

  DOI：10.1021/jm901532h

  日期：2010.4.8

  In an effort to increase the potency and selectivity of earlier identified substrate-based inhibitors of mitochondrial thymidine kinase 2 (TK-2), we now describe the synthesis of new thymidine analogues containing a 4- or 5-substituted 1,2,3-triazol-1-yl substituent at the 3'-position of the 2'-deoxyribofuranosyl ring. These analogues were prepared by Cu- and Ru-catalyzed cycloadditions of 3'-azido-3'-deoxythymidine and the appropriate alkynes, which produced the 1,4- and 1,5-triazoles, respectively. Selected analogues showed nanomolar inhibitory activity for TK-2, while virtually not affecting the TK-1 counterpart. Enzyme kinetics indicated a competitive and uncompetitive inhibition profile against thymidine and the cosubstrate ATP, respectively. This behavior is rationalized by suggesting that the inhibitors occupy the substrate-binding site in a TK-2 ATP complex that maintains the enzyme's active site in a closed conformation through the stabilization of a small lid domain.